Shots:

• The companies collaborated to identify targets for Otsuka’s therapeutics discovery programmes by leveraging PhoreMost’s expertise and next-generation phenotypic screening platform- SITESEEKER
• Otsuka will validate the novel targets identified in the collaboration as part of its internal development pipeline with an initial focus on gene therapy applications of identified targets
•  PhoreMost’s SITESEEKER platform deploys protein shape diversity to find functionally active peptides. Based on its PROTEINi technology- it utilizes SITESEEKER to probe the entire proteome in a live cell environment for novel targets linked to any disease

Click here ­to­ read full press release/ article | Ref: PhoreMost | Image: PhoreMost